secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-05-12T11:05:16+00:00
Accession:  0001193125-26-218142
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
- Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.
- GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.
- Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.
- Initial Phase 1 data for OP-3136 to be presented at ASCO 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/0001193125-26-218142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/olma-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer